Watch ROIV. Know when insiders buy.
One email the day a filing lands. Free.
Work order
57
WATCH · insiders 25, shorts 88
Insiders, 90 days
−$19.5M
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $25.2BP/E —DIV YIELD —FCF YIELD -3.25%REV TTM $7.5M −67.6%NET INCOME −$266.3MNET CASH $936.7M52W 12.91 – 37.58SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | $1.4M | −33.5% | — | −$366M | −$189.8M | — | -0.26 | −$270.5M | $419K | −$270.9M | Aug 6 |
| Q4 2026 · Mar 31derived | $2.5M | −66.7% | — | $415.2M | $303M | — | 0.34 | −$163.8M | $1.3M | −$165.1M | May 20 |
| Q3 2026 · Dec 31 | $2M | −77.8% | — | −$339.2M | −$265.9M | −257.0% | -0.38 | −$196.5M | −$4.9M | −$191.5M | Feb 6 |
| Q2 2026 · Sep 30 | $1.6M | −64.9% | — | −$306.2M | −$113.5M | — | -0.17 | −$185.7M | $7.8M | −$193.5M | Nov 10 |
| Q1 2026 · Jun 30 | $2.2M | −72.8% | — | −$284.9M | −$223.4M | −334.4% | -0.33 | −$204.4M | $4M | −$208.4M | Aug 6 |
| Q4 2025 · Mar 31derived | $7.6M | −16.1% | — | −$285M | −$206.5M | — | -0.29 | −$172.6M | $811K | −$173.4M | May 20 |
| Q3 2025 · Dec 31 | $9M | −42.1% | — | −$274.4M | $169.4M | −96.7% | 0.23 | −$207.3M | $1.8M | −$209.1M | Feb 6 |
| Q2 2025 · Sep 30 | $4.5M | +22.7% | — | −$341.7M | −$230.2M | — | -0.31 | −$266.8M | $996K | −$267.8M | Nov 10 |
| Q1 2025 · Jun 30 | $8M | — | — | −$102.2M | $95.3M | — | 0.12 | −$192.8M | $965K | −$193.8M | Aug 11 |
| Q4 2024 · Mar 31derived | $9M | — | — | −$206.8M | −$151.1M | — | -0.23 | −$108.5M | $349K | −$108.8M | May 20 |
| Q3 2024 · Dec 31 | $15.6M | — | — | $5.1B | $5.1B | — | 6.03 | −$210.5M | $355K | −$210.8M | Feb 10 |
| Q2 2024 · Sep 30 | $3.6M | — | — | −$213.9M | −$304.3M | — | -0.40 | −$196.4M | $275K | −$196.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | $8.3M | — | −$515.1M | −$299.8M | -3629.2% | -0.54 | −$750.3M | $8.2M | −$758.6M | — | — |
| FY2025 · to Mar 31 | $29.1M | — | −$1B | −$172M | -592.0% | -0.24 | −$839.5M | $4.6M | −$844M | $1.3B | — |
| FY2024 · to Mar 31 | $32.7M | — | $4.5B | $4.3B | 13294.2% | 5.23 | −$765.3M | $1.4M | −$766.6M | $0 | — |
| FY2023 · to Mar 31 | $31.5M | — | −$906.8M | −$1B | -3200.2% | -1.42 | −$843.4M | $12.7M | −$856.1M | $0 | — |
| FY2022 · to Mar 31 | $55.3M | — | −$1.4B | −$845.3M | -1528.9% | -1.26 | −$677.7M | $17.4M | −$695.2M | — | — |
| FY2021 · to Mar 31 | $23.8M | — | −$1.1B | −$809.2M | -3400.9% | -1.28 | −$552.1M | $5.8M | −$557.9M | — | — |
Every number comes from Roivant Sciences Ltd.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.